NCT05544292View on ClinicalTrials.gov

Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors

CompletedOBSERVATIONAL
Enrollment

69

Participants

Timeline

Start Date

March 5, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Immune-related Adverse Event
Interventions
OTHER

Antiinflammatory/DMARDs

Antiinflammatory/DMARDs

Trial Locations (5)

Unknown

Ålesund Hospital, Ålesund

Hospital of Southern Norway Trust, Kristiansand

Levanger Hospital, Levanger

Diakonhjemmet Hospital, Oslo

University Hospital of North Norway, Tromsø

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

Alesund Hospital

OTHER

collaborator

University Hospital of North Norway

OTHER

collaborator

Hospital of Southern Norway Trust

OTHER

collaborator

Helse Nord-Trøndelag HF

OTHER

lead

Diakonhjemmet Hospital

OTHER

NCT05544292 - Rheumatic IMmune-Related Adverse Events in Patients Treated With Immune Check Point Inhibitors | Biotech Hunter | Biotech Hunter